Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Pulse Biosciences (PLSE) Change in Acquisitions & Divestments (2020 - 2021)

Pulse Biosciences has reported Change in Acquisitions & Divestments over the past 2 years, most recently at $8.0 million for Q1 2021.

Quarterly results put Change in Acquisitions & Divestments at $8.0 million for Q1 2021, down 40.74% from a year ago — trailing twelve months through Dec 2021 was $8.0 million (down 77.14% YoY), and the annual figure for FY2021 was $8.0 million, down 77.14%.
Change in Acquisitions & Divestments for Q1 2021 was $8.0 million at Pulse Biosciences, down from $18.0 million in the prior quarter.
Over the last five years, Change in Acquisitions & Divestments for PLSE hit a ceiling of $18.0 million in Q4 2020 and a floor of -$9.0 million in Q2 2020.